Orion Pharma (ORIONPHARM) Stock Overview
Engages in the creation, discovery, development, manufacturing, and marketing of pharmaceutical products in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
ORIONPHARM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Orion Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳33.90 |
| 52 Week High | ৳73.10 |
| 52 Week Low | ৳25.20 |
| Beta | -0.52 |
| 1 Month Change | 21.51% |
| 3 Month Change | 7.96% |
| 1 Year Change | -52.39% |
| 3 Year Change | -59.35% |
| 5 Year Change | -21.71% |
| Change since IPO | -45.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORIONPHARM | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 8.7% | 2.7% | 2.8% |
| 1Y | -52.4% | -16.6% | -7.3% |
Return vs Industry: ORIONPHARM underperformed the BD Pharmaceuticals industry which returned -16.6% over the past year.
Return vs Market: ORIONPHARM underperformed the BD Market which returned -7.3% over the past year.
Price Volatility
| ORIONPHARM volatility | |
|---|---|
| ORIONPHARM Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BD Market | 7.2% |
| 10% least volatile stocks in BD Market | 3.1% |
Stable Share Price: ORIONPHARM has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: ORIONPHARM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 3,160 | Zareen Karim | www.orionpharmabd.com |
Orion Pharma Limited engages in the creation, discovery, development, manufacturing, and marketing of pharmaceutical products in Bangladesh. The company produces products in various dosage forms, including tablets, capsules, syrups, suspensions, injections, and dry powder for syrup/ suspension in various therapeutic groups, such as anticancer, antibiotics, anti-diabetics, anxiolytics, diuretics, cardiovascular drugs, etc. It also provides various vaccines and health-related consumer products, as well as generates and supplies electricity. The company was formerly known as Orion Laboratories Limited and changed its name to Orion Pharma Limited in October 2010.
Orion Pharma Limited Fundamentals Summary
| ORIONPHARM fundamental statistics | |
|---|---|
| Market cap | ৳7.93b |
| Earnings (TTM) | -৳109.39m |
| Revenue (TTM) | ৳6.19b |
Is ORIONPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORIONPHARM income statement (TTM) | |
|---|---|
| Revenue | ৳6.19b |
| Cost of Revenue | ৳4.40b |
| Gross Profit | ৳1.79b |
| Other Expenses | ৳1.90b |
| Earnings | -৳109.39m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 28.94% |
| Net Profit Margin | -1.77% |
| Debt/Equity Ratio | 105.9% |
How did ORIONPHARM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/12 13:27 |
| End of Day Share Price | 2025/07/10 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orion Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.